Recursion Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
18.6%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.92next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release and Business Update | 4 Nov 2026 |
| FY 2026 Annual Earnings Release and Business Update | 24 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Cash Operating Expense (Annual Burn Rate) Quarterly85.1MTarget: Less than 390 million USD for FY 2026
Cash, Cash Equivalents, and Restricted Cash Quarterly665.2MTarget: Maintain sufficient runway extending into early 2028
Quarterly Revenue Quarterly6.5MTarget: Expand collaboration-driven and milestone-based revenue
Watch Items
- FDA engagement and registrational study design alignment for REC-4881 in Familial Adenomatous Polyposis (FAP)Trigger: Alignment on endpoints and pivotal trial design in 2H 2026Action: Initiate registrational Phase 3 trial or adjust clinical development strategy
- REC-1245 Phase 1 dose escalation safety and tolerability dataTrigger: Additional dose escalation data in 2H 2026 with focus on hematologic toxicityAction: Determine recommended Phase 2 dose (RP2D) and advance to Phase 2 trials
- Go/no-go decisions for REC-7735 (PI3Kα H1047R inhibitor) and REC-102 (ENPP1 inhibitor)Trigger: Internal platform data review and decision points in 2H 2026Action: Formally advance programs to clinical development or terminate to optimize capital allocation
Research as of 20 Jun 2026